26309-99-9

Basic information

• Product Name: 6-ChloroMethyl-2,3-dihydro-benzo[1,4]dioxine
• Synonyms: 6-ChloroMethyl-2,3-dihydro-benzo[1,4]dioxine;4]dioxine;6-(chloroMethyl)-2;6-(chloromethyl)-2,3-dihydro-1,4-benzodioxine
• CAS NO: 26309-99-9
• Molecular Formula: C₉H₉ClO₂
• Molecular Weight: 184.61956
• Mol File: 26309-99-9.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 125-125 °C(Press: 0.07 Torr)
• Appearance: /
• Density: 1.264±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 6-ChloroMethyl-2,3-dihydro-benzo[1,4]dioxine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-ChloroMethyl-2,3-dihydro-benzo[1,4]dioxine(26309-99-9)
• EPA Substance Registry System: 6-ChloroMethyl-2,3-dihydro-benzo[1,4]dioxine(26309-99-9)

Safety Data

• Hazardous Substances Data: 26309-99-9(Hazardous Substances Data)

Usage

General Description

6-ChloroMethyl-2,3-dihydro-benzo[1,4]dioxine is a chemical compound with a molecular formula C8H9ClO2. It is a chlorinated derivative of 2,3-dihydro-benzo[1,4]dioxine and is used in organic synthesis and as an intermediate in the production of pharmaceuticals and agrochemicals. 6-ChloroMethyl-2,3-dihydro-benzo[1,4]dioxine has a chloromethyl group attached to the 6th carbon of the benzo[1,4]dioxine ring, making it a valuable building block for the preparation of various biologically active molecules. The exact uses and applications of this compound may vary depending on the specific synthetic pathway or chemical reaction in which it is involved.

Upstream product

• 493-09-4 benzo-1,4-dioxane 
• 50-00-0 formaldehyd 
• 39270-39-8 (2,3-dihydro-benzo[1,4]dioxin-6-yl)-methanol 
• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 20825-87-0 2,3-dihydrobenzo[1,4]dioxine-6-carboxylic acid ethyl ester 
• 3943-89-3 Ethyl protocatechuate 

Downstream Products

• 1147564-46-2 (PhMe(C₈H₇O₂CH₂)P)BH₃ 
• 166519-76-2 (2S,4R)-2-[(S)-1-(Benzyl-methyl-carbamoyl)-2-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethylcarbamoyl]-4-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 158574-76-6 [(S)-1-(Benzyl-methyl-carbamoyl)-2-(2,3-dihydro-benzo[1,4]dioxin-6-yl)-ethyl]-carbamic acid tert-butyl ester 
• 1026563-23-4 [2-cyano-5-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethoxy)-phenoxy]-o-tolyl-acetic acid methyl ester 
• 80985-34-8 6,7-bis(chloromethyl)-1,4-benzodioxan 

Relevant articles and documents

TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS

Compounds of formula (I') wherein A, R1, R2, T1, T2, T3, T4, L, W, Z, R''', m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.